Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

56 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Therapy-related acute lymphoblastic leukemia is a distinct entity with adverse genetic features and clinical outcomes.
Saygin C, Kishtagari A, Cassaday RD, Reizine N, Yurkiewicz I, Liedtke M, Stock W, Larson RA, Levine RL, Tallman MS, Park JH, Kerr C, Przychodzen B, Sekeres MA, Kalaycio ME, Carraway HE, Hamilton BK, Sobecks R, Gerds A, Mukherjee S, Nazha A, Maciejewski JP, Advani AS. Saygin C, et al. Blood Adv. 2019 Dec 23;3(24):4228-4237. doi: 10.1182/bloodadvances.2019000925. Blood Adv. 2019. PMID: 31869410 Free PMC article.
Emerging therapies for acute myeloid leukemia.
Saygin C, Carraway HE. Saygin C, et al. J Hematol Oncol. 2017 Apr 18;10(1):93. doi: 10.1186/s13045-017-0463-6. J Hematol Oncol. 2017. PMID: 28420416 Free PMC article. Review.
Genomic determinants of chronic myelomonocytic leukemia.
Patel BJ, Przychodzen B, Thota S, Radivoyevitch T, Visconte V, Kuzmanovic T, Clemente M, Hirsch C, Morawski A, Souaid R, Saygin C, Nazha A, Demarest B, LaFramboise T, Sakaguchi H, Kojima S, Carraway HE, Ogawa S, Makishima H, Sekeres MA, Maciejewski JP. Patel BJ, et al. Among authors: saygin c. Leukemia. 2017 Dec;31(12):2815-2823. doi: 10.1038/leu.2017.164. Epub 2017 May 30. Leukemia. 2017. PMID: 28555081 Free PMC article.
Prognostic impact of incomplete hematologic count recovery and minimal residual disease on outcome in adult acute lymphoblastic leukemia at the time of second complete response.
Saygin C, Papadantonakis N, Cassaday RD, Liedtke M, Fischer K, Dunn T, Patel BJ, Sobecks R, Kalaycio M, Sekeres MA, Mukherjee S, Gerds AT, Hamilton BK, Carraway HE, Advani AS. Saygin C, et al. Leuk Lymphoma. 2018 Feb;59(2):363-371. doi: 10.1080/10428194.2017.1344842. Epub 2017 Jul 11. Leuk Lymphoma. 2018. PMID: 28693363
Mutations in DNMT3A, U2AF1, and EZH2 identify intermediate-risk acute myeloid leukemia patients with poor outcome after CR1.
Saygin C, Hirsch C, Przychodzen B, Sekeres MA, Hamilton BK, Kalaycio M, Carraway HE, Gerds AT, Mukherjee S, Nazha A, Sobecks R, Goebel C, Abounader D, Maciejewski JP, Advani AS. Saygin C, et al. Blood Cancer J. 2018 Jan 10;8(1):4. doi: 10.1038/s41408-017-0040-9. Blood Cancer J. 2018. PMID: 29321554 Free PMC article. Clinical Trial.
Therapy for lower-risk MDS.
Carraway HE, Saygin C. Carraway HE, et al. Among authors: saygin c. Hematology Am Soc Hematol Educ Program. 2020 Dec 4;2020(1):426-433. doi: 10.1182/hematology.2020000127. Hematology Am Soc Hematol Educ Program. 2020. PMID: 33275714 Free PMC article.
56 results